Clinical trials: Viral Load
HCMV
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
- Trial name
- NCT02268526
- Testing
- CSJ148
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
HIV/AIDS, HIV-1-infection
Simplifying Treatment and Monitoring for HIV (STREAM HIV)
This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in…
- Trial name
- NCT04341779
- Testing
- Point-of-care viral load testing and tenofovir adherence testing
- Where
- South Africa
- Volunteers
- 539 people
- Sponsor
- University of Washington
HIV Infections
Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
Highly active antiretroviral therapy (HAART) has led to better health and survival rates among people with HIV/AIDS. The purpose of this study was to measure the effect of trained partner supervision when taking medication versus…
- Trial name
- NCT00608569
- Testing
- Lopinavir/ritonavir, Emtricitabine/Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate
- Where
- 9 sites in Botswana, Brazil and 6 more
- Volunteers
- 529 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection
Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine
The current study proposal is an open label observational trial for maintenance of virologic suppression, and is designed as a non- inferiority switch trial.
- Trial name
- NCT04538040
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Quest Clinical Research
Covid19
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization.
- Trial name
- COPPS (NCT04662060)
- Testing
- Acebilustat
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Human Immunodeficiency Virus, Depression
Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')
Many people with HIV infection are not consistently engaged in outpatient HIV care, and avoidance, stigma and denial contribute to poor engagement in HIV care.
- Conditions
- Human Immunodeficiency Virus, Depression, Anxiety
- Trial name
- NCT04481373
- Testing
- THRIVE, Treatment as Usual
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Baylor College of Medicine
HIV/AIDS, Medication Adherence
A Text-Based Adherence Game for Young People Living With HIV in Ghana
This study will develop and evaluate a game-based, text message intervention to promote adherence to HIV care among young people living with HIV (YPLH) in Ghana.
- Trial name
- TAG (NCT03928717)
- Testing
- Text-Based Adherence Game, Standard of Care (SOC)
- Where
- Ghana
- Volunteers
- 60 people
- Sponsor
- Rhode Island Hospital
COVID-19
The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients
Existing evidence confirmed that saliva and oral cavity to be a reservoir for SARS-CoV-2. In dental clinic aerosol-producing-procedures pose a significant risk for transmission of the infection .
- Trial name
- NCT04941131
- Testing
- Chlorhexidine digluconate, povidone iodine
- Where
- Saudi Arabia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- King Abdulaziz University
Human Immunodeficiency Virus
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients.
- Trial name
- NCT01097655
- Volunteers
- 3,049 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections, Herpes Genitalis
Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda
This study will determine whether acyclovir, a medicine used to treat herpes simplex virus 2 (HSV-2), can slow down the progression (worsening) of HIV disease in people with both HIV and HSV-2 infections.
- Trial name
- NCT00405821
- Testing
- Acyclovir
- Where
- Uganda
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM)…
- Trial name
- NCT02833844
- Testing
- Evolocumab
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 467 people
- Sponsor
- Amgen
HIV
Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
This study will examine the effects of atorvastatin, a statin (drug that lowers cholesterol) on the human immunodeficiency virus (HIV).
- Trial name
- STATIN (NCT00367458)
- Testing
- Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
This is an Australian, open-label, multicenter, randomized, double-blind clinical trial designed to assess the efficacy of combination therapy with pegylated interferon alfa-2b and ribavirin for 48 weeks versus 24 weeks in the…
- Trial name
- NCT00255034
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs.
- Trial name
- NCT00515827
- Testing
- Raltegravir (MK-0518)
- Where
- 20 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if…
- Trial name
- NCT00039741
- Testing
- NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 266 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
Different immunosuppressive drugs used in transplantation may reduce the body's defences against infection differently. It is known that patients with Hepatitis C virus, known as HCV, who switched from azathioprine to…
- Trial name
- NCT01134952
- Testing
- Mycophenolate to sirolimus switch
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- London Health Sciences Centre
Chronic HIV Infection
Optimizing Viral Load Suppression in Kenyan Children on Antiretroviral Therapy
Among nearly 1 million HIV-infected children receiving antiretroviral treatment (ART), as many as 40% of those living in resource limited settings have not achieved virologic suppression.
- Trial name
- Opt4Kids (NCT03820323)
- Testing
- POC VL and targeted DRM testing., SOC VL testing
- Where
- Kenya
- Volunteers
- 704 people
- Sponsor
- University of Alabama at Birmingham
HIV, Pregnancy
Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya
The goal of this project is to rigorously evaluate the efficacy of HIV Infant Tracking System 2.1 (HITSystem, an eHealth intervention that uses short message service (SMS) texts to patients and algorithm-driven electronic alerts…
- Trial name
- NCT04571684
- Testing
- HITSystem 2.1
- Where
- 12 sites in Kenya
- Volunteers
- 1,639 people
- Sponsor
- University of Kansas Medical Center
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- NCT01335191
- Testing
- TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thymon, LLC
COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019…
- Trial name
- COMET-PACE (NCT05124210)
- Testing
- Sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline